TY - JOUR
AR - COR-2020-9-107
TI - Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia
AU - Andras , Szasz
JO - Clinical Oncology and Research
PY - 2020
DA - Fri 18, Sep 2020
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2020.09.07
UR - https://www.sciencerepository.org/towards-the-immunogenic-hyperthermic-action-modulated-electro-hyperthermia_COR-2020-9-107 
KW - Hyperthermia, oncology, immunogenic cell death
AB - Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use.
Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a
novel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination,
presenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is
approved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.